Breaking the cycle: PRMTs and secondary HLH relief.

作者信息

Malik Sakshi, Chandrakasan Shanmuganathan

机构信息

Bone Marrow Transplantation Program, Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Department of Pediatrics, Emory University School of Medicine, Atlanta, GA.

出版信息

Blood Adv. 2025 May 27;9(10):2436-2437. doi: 10.1182/bloodadvances.2025015863.

DOI:10.1182/bloodadvances.2025015863

PMID:40372747

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12235310/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2188/12235310/6e679dd3f08e/BLOODA_ADV-2025-015863-C-gr1.jpg

相似文献

[1]

Breaking the cycle: PRMTs and secondary HLH relief.

Blood Adv. 2025-5-27

[2]

Characteristics of 21 Patients with Secondary Hemophagocytic Lymphohistiocytosis-Insights from a Single-Center Retrospective Study.

Medicina (Kaunas). 2025-5-26

[3]

Secondary hemophagocytic lymphohistiocytosis associated with adjuvant pembrolizumab therapy in a young patient with triple-negative breast cancer: a case report with literature review.

Arch Gynecol Obstet. 2025-7-3

[4]

X-Linked Lymphoproliferative Disease

1993

[5]

Emapalumab treatment in rheumatologic disease-associated hemophagocytic lymphohistiocytosis: a plain language summary.

Immunotherapy. 2025-5

[6]

Ocular inflammation as the first presenting feature of PRF1-associated familial hemophagocytic lymphohistiocytosis, case report and review of literature.

BMC Ophthalmol. 2025-7-7

[7]

Secondary hemophagocytic lymphohistiocytosis in zoonoses. A systematic review.

Eur Rev Med Pharmacol Sci. 2012-10

[8]

Fatal HLH in patients with X-linked lymphoproliferative disease 1 due to a novel variant in : case report.

Front Immunol. 2025-5-19

[9]

Optimizing hemophagocytic lymphohistiocytosis screening in children: validation of the HLH-Screen score.

Ann Hematol. 2025-6-20

[10]

Diagnosing and treating hemophagocytic lymphohistiocytosis in the tropics: systematic review from the Indian subcontinent.

Acta Med Acad. 2012

本文引用的文献

[1]

PRMT5 inhibition reduces hyperinflammation in a murine model of secondary hemophagocytic lymphohistiocytosis.

Blood Adv. 2025-5-27

[2]

The Role of PRMT5 in Immuno-Oncology.

Genes (Basel). 2023-3-9

[3]

Control of protein stability by post-translational modifications.

Nat Commun. 2023-1-13

[4]

Protein Arginine Methyltransferase 5 (PRMT5) Inhibitors in Oncology Clinical Trials: A review.

J Immunother Precis Oncol. 2022-6-22

[5]

PRMT5 Is Required for T Cell Survival and Proliferation by Maintaining Cytokine Signaling.

Front Immunol. 2020

[6]

PRMT5 is essential for B cell development and germinal center dynamics.

Nat Commun. 2019-1-3

[7]

Janus kinase inhibition lessens inflammation and ameliorates disease in murine models of hemophagocytic lymphohistiocytosis.

Blood. 2016-3-31

[8]

Repeated TLR9 stimulation results in macrophage activation syndrome-like disease in mice.

J Clin Invest. 2011-5-16

[9]

Prmt5 is essential for early mouse development and acts in the cytoplasm to maintain ES cell pluripotency.

Genes Dev. 2010-12-15

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

新学期，新优惠

Breaking the cycle: PRMTs and secondary HLH relief.

作者信息

机构信息

出版信息

相似文献

本文引用的文献

文献AI研究员

用中文搜PubMed

推荐工具

Suppr 超能文献

相似文献

本文引用的文献